Close

Rosetta wins European patent covering core element of microRNA technology

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

Rosetta Genomics has won a European patent covering the use of miR-34a in the preparation of pharmaceuticals used to treat p53-negative cancers.

The patent covers a core element of Rosetta’s microRNA technology in the development of cancer therapeutics associated with p53-negative cancers. Rosetta Genomics president and chief executive officer Kenneth Berlin said, “This patent is important as it protects key elements of our microRNA technology to develop treatments for a variety of cancers.”

The issued patent is collectively owned with Yeda, the technology transfer company of the Weizmann Institute of Science. The miR-34a is a direct transcriptional target of p53, which may mediate some of the biological effects of the tumor suppressor.

Latest stories